UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 25, 2015
Atara Biotherapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-36548 |
|
46-0920988 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer Identification No.) |
|
701 Gateway Boulevard, Suite 200 South San Francisco, CA |
|
94080 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (650) 278-8930
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 25, 2015, Atara Biotherapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2015.
The stockholders of the Company voted on the following proposals at the Annual Meeting:
|
1. |
To elect three directors to serve until the 2018 annual meeting of stockholders and until his or her successor has been duly elected. |
|
2. |
To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015. |
The voting results for each of these proposals are detailed below:
|
1. |
Election of Directors |
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Eric L. Dobmeier |
14,905,371 |
6,933 |
2,053,710 |
|
Beth Seidenberg |
14,260,577 |
651,727 |
2,053,710 |
|
Eckard Weber |
14,876,707 |
35,597 |
2,053,710 |
Each of the three nominees for director was elected to serve until the 2018 annual meeting of stockholders and until their successors are elected.
|
2. |
Ratification of Appointment of Independent Registered Public Accounting Firm |
|
For |
Against |
Abstentions |
|
16,964,935 |
941 |
138 |
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Atara Biotherapeutics, Inc. |
||
|
|
||
|
|
|
|
|
By: |
|
/s/ John F. McGrath, Jr. |
|
|
|
John F. McGrath, Jr. |
|
|
|
Chief Financial Officer |
Date: June 29, 2015